DoW Lupus, Transformative Vision Development Award

About this funding opportunity

Summary: This funding mechanism supports planning and development activities and pilot studies that will generate preliminary data and demonstrate feasibility for achieving the aims of a future interventional study. Successful studies may be submitted to a future Lupus Research Program (LRP) Transformative Vision Award (TVA), or equivalent, for funding consideration (See Funding Opportunity Number HT942526LRPTVA for additional information). Research must address at least one of the fiscal year 2026 (FY26) LRP Transformative Vision Development Award (TVDA) focus areas. This funding mechanism allows for phase 0/1 clinical trials, if appropriate. The mechanism does not allow for phase 2/3 clinical trials or animal studies.

Distinctive Features:

• Preliminary data are permitted but not required.

• Applications must include at least one lupus consumer advocate as a member of the research team.

• An individual may be named as Principal Investigator (PI) on only one application per LRP award mechanism (Idea Award, Impact Award, TVDA, TVA), for a maximum of four applications to the FY26 LRP.

Topic areas: General and Cross-cutting R&D, Life Sciences and Health.

Funding amount

This grant provides Varies in funding.

Deadline

Applications are due Aug 24, 2026. Confirm the exact closing time on the official program page before applying.

Who can apply

This opportunity is open to the following applicant types:

• Open to all applicant types

Eligibility

The program did not publish a separate eligibility statement. See the official opportunity page for the full eligibility criteria.

Agency

DoW Lupus, Transformative Vision Development Award is administered by Defense Health Agency Contracting Activity - DHACA (AMRAA), listed via Grants.gov.